Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

INSM – Insmed Incorporated

Insmed Incorporated
INSM
$100.10
Name : Insmed Incorporated
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $19,013,146,624.00
EPSttm : -5.93
finviz dynamic chart for INSM
Insmed Incorporated
$100.10
0.61%
$0.605

Float Short %

6.27

Margin Of Safety %

Put/Call OI Ratio

1.32

EPS Next Q Diff

0.05

EPS Last/This Y

0.38

EPS This/Next Y

1.61

Price

99.5

Target Price

112

Analyst Recom

1.05

Performance Q

28.06

Relative Volume

10.91

Beta

0.88

Ticker: INSM




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02INSM71.71.094.1578184
2025-06-03INSM73.081.116.6979723
2025-06-04INSM73.691.210.5483249
2025-06-05INSM72.741.141.4787562
2025-06-06INSM73.781.160.0788493
2025-06-09INSM70.641.121.9893116
2025-06-10INSM90.881.130.9998814
2025-06-11INSM92.551.170.94100423
2025-06-12INSM971.200.48108046
2025-06-13INSM98.761.160.88113791
2025-06-16INSM101.61.171.36115473
2025-06-17INSM100.281.181.93116531
2025-06-18INSM99.451.200.20117418
2025-06-20INSM102.691.201.39117650
2025-06-23INSM105.461.371.3364647
2025-06-24INSM105.91.371.5566193
2025-06-25INSM104.841.370.1767517
2025-06-26INSM101.71.380.5667807
2025-06-27INSM99.491.320.6069328
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02INSM71.6832.3-13.6-5.16
2025-06-03INSM73.0832.3-5.9-5.16
2025-06-04INSM73.7032.34.3-5.16
2025-06-05INSM72.7432.324.0-5.16
2025-06-06INSM73.5932.41.4-5.16
2025-06-09INSM70.6832.448.9-5.16
2025-06-10INSM90.8532.4-250.7-5.16
2025-06-11INSM97.9832.4-59.2-5.16
2025-06-12INSM96.8832.422.5-5.16
2025-06-13INSM98.7932.9-5.3-5.15
2025-06-16INSM101.6032.2-13.8-5.19
2025-06-17INSM100.3332.224.2-5.19
2025-06-18INSM99.4632.220.3-5.19
2025-06-20INSM102.6832.2-16.9-5.19
2025-06-23INSM105.4132.2-11.6-5.19
2025-06-24INSM105.9332.28.4-5.19
2025-06-25INSM104.8032.222.4-5.19
2025-06-26INSM101.6932.240.1-5.19
2025-06-27INSM99.5032.233.1-5.19
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02INSM-17.014.509.25
2025-06-03INSM-17.444.509.25
2025-06-04INSM-17.444.509.25
2025-06-05INSM-17.884.509.25
2025-06-06INSM-17.884.509.25
2025-06-09INSM-17.914.419.29
2025-06-10INSM-15.814.419.29
2025-06-11INSM-15.814.419.85
2025-06-12INSM-19.194.419.85
2025-06-13INSM-21.844.419.81
2025-06-16INSM-20.764.249.81
2025-06-17INSM-20.914.249.81
2025-06-18INSM-22.994.249.40
2025-06-20INSM-22.994.249.40
2025-06-23INSM-22.634.229.40
2025-06-24INSM-22.714.229.40
2025-06-25INSM-23.524.229.40
2025-06-26INSM-23.524.226.27
2025-06-27INSM-23.524.226.27
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-1.42

Avg. EPS Est. Current Quarter

-1.31

Avg. EPS Est. Next Quarter

-1.37

Insider Transactions

-23.52

Institutional Transactions

4.22

Beta

0.88

Average Sales Estimate Current Quarter

103

Average Sales Estimate Next Quarter

113

Fair Value

Quality Score

30

Growth Score

53

Sentiment Score

83

Actual DrawDown %

6.9

Max Drawdown 5-Year %

-63.3

Target Price

112

P/E

Forward P/E

PEG

P/S

49.6

P/B

182.51

P/Free Cash Flow

EPS

-5.95

Average EPS Est. Cur. Y​

-5.19

EPS Next Y. (Est.)

-3.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-265.93

Relative Volume

10.91

Return on Equity vs Sector %

-1045.8

Return on Equity vs Industry %

-1027.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.14

EBIT Estimation

33.1
Insmed Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 1271
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
stock quote shares INSM – Insmed Incorporated Stock Price stock today
news today INSM – Insmed Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch INSM – Insmed Incorporated yahoo finance google finance
stock history INSM – Insmed Incorporated invest stock market
stock prices INSM premarket after hours
ticker INSM fair value insiders trading